University of Kansas

Georgetown University

Fox Chase Cancer Center

Andrew Godwin

Erica A Golemis

Louis M Weiner

Mei He

Ilya G Serebriiskii

Igor Astsaturov

Yong Zeng

Vladimir Ratushny

A microfluidic exosome profiling platform integrating exosome isolation and targeted proteomic analysis is disclosed. This platform is capable of quantitative exosomal biomarker profiling directly from 30 &#x3bc;L plasma samples within approximately 100 minutes with markedly enhanced sensitivity and specificity. Identification of distinct subpopulation of patient-derived exosomes is demonstrated by probing surface proteins and multiparameter analyses of intravesicular biomarkers in the selected subpopulation. The expression of IGF-1R and its phosphorylation level in non-small cell lung cancer (NSCLC) patient plasma is assessed, as a non-invasive alternative to the conventional biopsy and immunohistochemistry. The microfluidic chip, which may be fabricated of a glass substrate and a layer of poly(dimethylsiloxane), can include a first capture chamber, a second capture chamber, a serpentine microchannel, a first microchannel, a second microchannel, a sample inlet, a buffer inlet, a bead inlet, at least a first connector channel, and a reagent inlet.

Non-invasive monitoring cancer using integrated microfluidic profiling of circulating microvesicles

Compositions which act synergistically to inhibit the growth of cancer cells and methods of use thereof are disclosed.

Combination therapy based on SRC and aurora kinase inhibition for the treatment of cancer

Growing community of inventors

Leawood, KS, United States of America

Andrew Godwin